BioAge Labs(BIOA) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BIOA BioAge Labs

Watchlist

4.320
-0.060-1.37%

Trading Mar 21 10:07 ET

154.87MMarket Cap-2.18P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

William Blair Sticks to Its Hold Rating for BioAge Labs, Inc. (BIOA)
TipRanks07:27 ET · Ratings
BioAge Labs | 10-K: Annual report
SEC17:05 ET · Announcements
BioAge Labs | 8-K: BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
SEC16:54 ET · Announcements
BioAge Labs FY24 EPS $(6.63) Up From $(38.17) YoY
Benzinga16:33 ET
BioAge Labs: Existing Cash and Cash Equivalents Sufficient to Fund Ops and Cap Expenses Through 2029 >BIOA
Dow Jones16:33 ET
BioAge Labs FY24 Loss $71.1M >BIOA
Dow Jones16:33 ET

Comments

Teddy123

9 hours ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

$BioAge Labs (BIOA.US)$
BioAge Labs Lands Massive $550M Novartis Deal Despite Clinical Setback in 2024 Results

Teddy123

Mar 18 09:24

BioArctic receives Orphan Drug Designation for exidavnemab the US

$BioAge Labs (BIOA.US)$
BioArctic Secures Crucial FDA Designation for Rare Fatal Disease Treatment

Trytosaveabit

Mar 18 02:13

News

$BioAge Labs (BIOA.US)$ BioArctic AB (Nasdaq Stockholm: BIOA B) has received Orphan Drug Designation from the US FDA for exidavnemab, targeting the treatment of Multiple System Atrophy (MSA). MSA is a rare, fatal disease affecting the central and autonomic nervous systems, characterized by alpha-synuclein aggregation that damages brain nerve cells.
Exidavnemab is being developed as a disease-modifying treatment for synucleinopathies including MSA and Parkinson's disease. As a monoclonal antib...